Belite Bio Says FDA Extends Tinlarebant NDA Review, Sets May 12, 2027 PDUFA Action Date
Benzinga Newsdesk 16 hours ago
NewsFDA
Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio®" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have
Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio®" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that (i) it has extended the review period for the New Drug Application (NDA) for tinlarebant for the treatment of Stargardt disease type 1 (STGD1) by three months, with the extended Prescription Drug User Fee Act (PDUFA) action date being May 12, 2027, and (ii) if no major deficiencies are identified during FDA’s ongoing review, the FDA plans to communicate proposed labeling requests and any anticipated postmarketing requirement requests, if necessary, with the Company by April 12, 2027.
The extension provides the FDA with additional time to review information provided in support of the NDA. Belite Bio remains committed to working closely with FDA throughout the review process, and is confident in the clinical evidence supporting tinlarebant and its potential to address the significant unmet medical need in the STGD1 patient population.
More on BLTE
FDA & biotech Benzinga
Belite Bio Stock Plunges After FDA Extends Review TimelineBelite Bio shares are sinking Friday after the FDA added three months to its review timeline of the company's application for tinlarebant.

